We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
- Authors
Millot, F; Suciu, S; Philippe, N; Benoit, Y; Mazingue, F; Uyttebroeck, A; Lutz, P; Mechinaud, F; Robert, A; Boutard, P; Marguerite, G; Ferster, A; Plouvier, E; Rialland, X; Behard, C; Plantaz, D; Dresse, M F; Philippet, P; Norton, L; Thyss, A; Dastugue, N; Waterkeyn, C; Vilmer, E; Otten, J; Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer
- Abstract
The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Vol 19, Issue 7, p1935
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2001.19.7.1935